

S 2956

Patients First Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: May 24, 2018

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (May 24, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/2956>

Sponsor

Name: Sen. Wicker, Roger F. [R-MS]

Party: Republican • State: MS • Chamber: Senate

Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Blunt, Roy [R-MO]	R · MO		May 24, 2018
Sen. Daines, Steve [R-MT]	R · MT		May 24, 2018
Sen. Lankford, James [R-OK]	R · OK		May 24, 2018
Sen. Inhofe, James M. [R-OK]	R · OK		Jun 11, 2018
Sen. Hyde-Smith, Cindy [R-MS]	R · MS		Jul 31, 2018

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	May 24, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 2918	Related bill	Jun 16, 2017: Referred to the Subcommittee on Health.

Patients First Act of 2018

This bill amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions, provided that the techniques will not involve: (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a living human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this bill.

HHS must issue guidelines to ensure that any research (including any clinical trial) supported under this bill: (1) is clearly consistent with the standards established in this bill, if conducted using human cells; and (2) is prioritized in terms of potential for near-term clinical benefit in human patients.

HHS must report on peer reviewed stem cell research proposals that were not funded.

Actions Timeline

- **May 24, 2018:** Introduced in Senate
- **May 24, 2018:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.